STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #661 by analyst upside · 2026-06-27
VOR
Vor Biopharma Inc.
Healthcare · Market Cap $872M · P/E 0x
ANALYST PRICE TARGET
+135.2%
implied upside to consensus target
Current Price $16.1
Consensus Target $37.88
Bull Target $50.0
Bear Target $18.0
Analysts Covering 8
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
6
Hold
1
Sell
0
52-Week Low $6.5
52-Week High $65.8
YTD Return +38.3%
FUNDAMENTALS
Market Cap $872M
P/E Ratio (TTM) N/A
Forward P/E -4.3x
EPS (TTM) $-70.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.5
52-Week High $65.8
Current Price $16.1
Bear Target $18.0
Bull Target $50.0
● Now $16.1 ● Target $37.88
TRADING DATA
Avg Volume 1.0M
YTD Return +38.3%
Analyst Count 8
Consensus Buy
Upside to Target +135.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Vor Biopharma Inc. (VOR) is currently trading at $16.1 with a Wall Street consensus price target of $37.88, implying potential upside of 135.2% over the next 12 months. 8 analysts currently cover VOR, with a consensus rating of Buy — 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $18.0.

VOR operates in the Healthcare sector with a market capitalisation of $872M. The stock is up 38.3% year-to-date and is currently trading near the lower end of its 52-week range of $6.5 – $65.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VOR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-18 31% win rate (48 calls)
Wedbush — Reiterated
Neutral → Neutral 2026-05-14 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-04-15 31% win rate (48 calls)
Wedbush — Reiterated
Neutral → Neutral 2026-03-31 Building track record
Jefferies ● Initiated
Buy 2026-03-30 50% win rate (6 calls)
Wells Fargo ● Initiated
Overweight 2026-03-19 Building track record
Citigroup ● Initiated
Buy 2026-01-09 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2025-12-19 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →